Table 4

Associations of breast cancer risk with IGF-I, IGF-II, and IGFBP-3 in pre- and postmenopausal women

VariableNumberUnadjustedNumberAdjustedaAdjustedb
Case/controlOR95% CICase/controlOR95% CIOR95% CI
Premenopausal women
IGF-I by tertile (ng/ml)
  ≤125.833/561.0032/561.001.00
  125.9–170.060/581.780.98–3.2255/561.650.85–3.211.460.70–3.03
  >170.078/562.411.35–4.2974/552.291.20–4.371.920.88–4.20
  Trend testP = 0.003P = 0.012P = 0.236
IGF-II by tertile (ng/ml)
  <718.752/561.0050/541.00
  718.8–936.553/581.320.61–2.8950/581.170.50–2.71
  >936.566/561.960.74–5.2161/551.500.51–4.44
  Trend testP = 0.154P = 0.439
IGFBP-3 by tertile (ng/ml)
  ≤359336/561.0035/561.001.00
  3594–425852/571.540.86–2.7548/561.350.72–2.540.980.47–2.06
  >425883/573.431.72–6.8778/553.711.67–8.262.691.12–6.47
  Trend testP < 0.001P = 0.002P = 0.022
Postmenopausal women
IGF-I by tertile (ng/ml)
  ≤94.4739/431.0038/431.001.00
  94.5–121.732/440.820.41–1.6728/420.660.27–1.590.570.22–1.43
  >121.757/431.520.80–2.8856/411.970.93–4.191.560.68–3.57
  Trend testP = 0.155P = 0.042P = 0.166
IGF-II by tertile (ng/ml)
  ≤703.439/431.0038/411.00
  703.5–962.241/431.080.59–1.9939/431.080.53–2.18
  >962.2 ng/ml48/442.130.72–6.3345/422.170.60–7.90
  Trend testP = 0.281P = 0.367
IGFBP-3 by tertile (ng/ml)
  ≤377926/431.0025/401.001.00
  3780–486347/431.650.88–3.0744/421.520.75–3.101.400.65–2.98
  >486355/442.371.08–5.1853/442.601.03–6.562.110.76–5.87
  Trend testP = 0.027P = 0.044P = 0.178
  • a Adjusted for BMI, age at menarche, age at first live birth, total energy intake, WHR, history of fibroadenoma, and family history of breast cancer.

  • b Adjusted for BMI, age at menarche, age at first live birth, total energy intake, WHR, history of fibroadenoma, family history of breast cancer, and either IGFBP-3 or IGF-I.